SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28
http://www.w3.org/2000/01/rdf-schema#comment
"aberrantly activated AREG-EGFR signaling is required for CRTC1-MAML2-positive MEC cell growth and survival suggesting that EGFR-targeted therapies will benefit patients with advanced unresectable CRTC1-MAML2-positive MEC."
xsd:string
http://purl.uniprot.org/uniprot/#_374A92739AA87874F379B86F9C58539AA1053B83B7E647AB61C97A86C4D2C4A7F064A5BF3761881C87E389DF44B8E8B0
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28
http://purl.uniprot.org/uniprot/B7ZL21
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28
http://purl.uniprot.org/uniprot/#_B7ZL21-mappedCitation-23975434
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C0EAA146BB72853F96E10F36E6D27466E4DE42107BA5D95C59D48C74E6FEF7277D97FA9DB104FE03827A634B03D38F28